University of Southampton, Southampton UK.
University of Southampton, Southampton UK; University Hospitals Southampton NHS FT, Southampton UK.
Urology. 2021 Feb;148:8-25. doi: 10.1016/j.urology.2020.10.024. Epub 2020 Oct 28.
There is growing evidence suggesting cannabinoids may provide suitable alternatives to conventional treatments in an increasing number of clinical settings. This review evaluates how cannabinoids are used to treat certain benign urological pathologies and to clarify the clinical value of this data. This review includes 62 papers and was undertaken per PRISMA's guidelines, it evidences the therapeutic potential of cannabinoids in the management of specific benign urological diseases, most notably neurogenic bladder dysfunction (clinical studies), renal disease (animal studies), and interstitial cystitis (animal studies). However, whilst cannabinoids are increasingly used, they cannot be considered reliable alternatives to more recognised treatments.
越来越多的证据表明,大麻素可能在越来越多的临床环境中为传统治疗提供合适的替代品。本综述评估了大麻素如何用于治疗某些良性泌尿科疾病,并阐明了这方面数据的临床价值。本综述包括 62 篇论文,是根据 PRISMA 的指南进行的,它证明了大麻素在管理特定良性泌尿科疾病方面的治疗潜力,尤其是神经源性膀胱功能障碍(临床研究)、肾脏疾病(动物研究)和间质性膀胱炎(动物研究)。然而,尽管大麻素的应用越来越广泛,但它们不能被认为是更被认可的治疗方法的可靠替代品。